BCR and acute lymphoblastic leukemia: While dasatinib significantly delayed the progression of 11 PDXs relative to control vehicle-treated mice, the only PDX that sustained a prolonged regression was the ALL-4 PDX that harbored a BCR::ABL1 fusion.